Sinovac vaccination and the course of COVID-19 disease in hospitalized patients in Turkey

1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.. "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan" , China JAMA. 2020; 323(11):1061–9. doi: DOI: 10.1001/jama.2020.1585

2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, "China Medical Treatment Expert Group for Covid-19" . New England journal of medicine2020; 382(18): 1708–20. DOI: 10.1056/NEJMoa2002032

3. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al.. "Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019" . J Intern Med. 2020; 288(3):335–44. doi: DOI: 10.1111/joim.13089

4. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al.. "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan" , China. Allergy. 2020; 75(7):1730–41. doi: DOI: 10.1111/all.14238.

5. "Worldometer: Coronavirus" ( https://www.worldometers.info/coronavirus/)

6. "COVID-19 Bilgilendirme Platformu" ( https://covid19.saglik.gov.tr).

7. Velavan TP, Meyer CG. "The COVID-19 epidemic" . Trop Med Int Health.2020; 25(3):278–80. doi: DOI: 10.1111/tmi.13383

8. Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, et al.. "The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem" . J Biol Regul Homeost Agents. 2021; 35(1):1–4. doi: DOI: 10.23812/21-3-E. PMID: 33377359.

9. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh I.K, Singh A, et al.. "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach" . Biochim. Biophys. Acta Mol. Basis Dis. 2020; 1866(10):165878. doi: DOI: 10.1016/j.bbadis.2020.165878. PMID: 32544429; PMID: PMC7293463

10. Mishra SK, Tripathi T. "One year update on the COVID-19 pandemic: Where are we now?" . Acta Trop. 2021Feb; 214:105778. doi: DOI: 10.1016/j.actatropica.2020.105778. PMID: 33253656; PMID: PMC7695590.

11. Wang R, Hozumi Y, Yin C, Wei GW. "Mutations on COVID-19 diagnostic targets" . Genomics.2020; 112(6):5204–13. doi: DOI: 10.1016/j.ygeno.2020.09.028

12. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ETBarrett KMS, et al.. "Emergence and rapid transmission of SARSCoV-2 B.1.1.7 in the United States" . Cell. 2021; 184(10):2587–94.e.13. doi: DOI: 10.1016/j.cell.2021.03.052.

13. Aleem A, Akbar Samad AB, Slenker AK. "Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). 2021 Apr 11" . In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021Jan–. PMID: 34033342.

14. Davies NG, Barnard RC, Jarvis CI, Kucharski AJ, Munday J, Pearson CAB, et al.. "Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England" . MedRxiv.2020.12.24. 20248822. doi: DOI: 10.1101/2020.12.24.20248822

15. Gupta R, Misra A. "Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc)" . Diabetes Metab Syndr.2020; 14(3):251–4. doi: DOI: 10.1016/j.dsx.2020.03.012.

16. Villoutreix BO, Calvez V, Marcelin AG, Khatib AM. "In Silico Investigation of the New UK (B.1.1.7) and South African (501Y. V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface" . Int J Mol Sci.2021; 22(4):1695. doi: DOI: 10.3390/ijms22041695. PMID: 33567580; PMID: PMC7915722.

17. Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. "Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?" . Int J Infect Dis. 2020; 96:459–60. doi: DOI: 10.1016/j.ijid.2020.05.071

18. Grabowski F, Preibisch G, Giziński S, Kochańczyk M, Lipniacki T. "SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations" . Viruses.2021; 13(3):392. doi: DOI: 10.3390/v13030392. PMID: 33804556; PMID: PMC8000749.

19. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al.. "Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus" . Cell. 2020; 182:812–27e819. doi: DOI: 10.1016/j.cell.2020.06.043.

20. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Jewell NP, Diaz-Ordaz K, Keogh RH, et al.. "Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01" . Preprint. medRxiv. 2021;2021.02.01.21250959. doi: DOI: 10.1101/2021.02.01.21250959

21. Lorenzo-Redondo R, Nam HH, Roberts SC, Simons LM, Jennings LJ, Qi C, et al.. "A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways" . EBioMedicine. 2020Dec; 62:103112. doi: DOI: 10.1016/j.ebiom.2020.103112. PMID: 33186810; PMID: PMC7655495.

22. Groves DC, Rowland-Jones SL, Angyal A. "The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design" . Biochem Biophys Res Commun. 2021; 538:104–7. doi: DOI: 10.1016/j.bbrc.2020.10.109

23. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al.. "Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England" . Nature. 2021; 593(7858):266–9. doi: DOI: 10.1038/s41586-021-03470-x

24. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al.. "The impact of COPD and smoking history on the severity of Covid-19: a systemic review and meta-analysis" . J Med Virol. 2020Oct; 92(10):1915–21. doi: DOI: 10.1002/jmv.25889

25. Kant A, Comoglu S, Ozturk S, Aydin E, Yilmaz G. "Does Chronıc Obstructıve Lung Dısease Affect The Severıty Of Covıd-19 Infectıon?" . Kırıkkale University Faculty Of Medicine Journal, 2020: 22 (3), 440–4. doi: DOI: 10.24938/Kutfd.810344

26. Uddin M, Mustafa F, Rizvi TA, Loney T, Al Suwaidi H, Al-Marzouqi AHH, et al.. "SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions" . Viruses. 2020; 12(5):526. doi: DOI: 10.3390/v12050526. PMID: 32397688; PMID: PMC7290442.

27. Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, et al.. "The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem" . J Biol Regul Homeost Agents. 2021; 35(1):1–4. doi: DOI: 10.23812/21-3-E. PMID: 33377359.

28. Yadav T, Srivastava N, Mishra G, Dhama K, Kumar S, Puri B, et al.. "Recombinant vaccines for COVID-19" . Hum Vaccin Immunother. 2020; 16(12):2905–12. doi: DOI: 10.1080/21645515.2020.1820808

29. Knoll MD, Wonodi C. "Oxford-AstraZeneca COVID-19 vaccine efficacy" . Lancet.2021; 397(10269):72–4. doi: DOI: 10.1016/S0140-6736(20)32623-4

30. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. "What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2" . Lancet Infect Dis.2021; 21(2):e26–e35. doi: DOI: 10.1016/S1473-3099(20)30773-8. PMID: 33125914; PMID: PMC7837315.

留言 (0)

沒有登入
gif